{"id":"NCT01606761","sponsor":"Janssen Research & Development, LLC","briefTitle":"A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)","officialTitle":"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-08-06","primaryCompletion":"2015-03-17","completion":"2016-01-12","firstPosted":"2012-05-28","resultsPosted":"2018-02-05","lastUpdate":"2018-03-23"},"enrollment":878,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Arthritis, Rheumatoid"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Sirukumab","otherNames":[]},{"type":"DRUG","name":"Sirukumab","otherNames":[]},{"type":"DRUG","name":"Sirukumab","otherNames":[]}],"arms":[{"label":"Group 1","type":"EXPERIMENTAL"},{"label":"Group 2","type":"EXPERIMENTAL"},{"label":"Group 3","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the efficacy of sirukumab as measured by the reduction of the signs and symptoms of rheumatoid arthritis (RA) in patients with active RA who are unresponsive or intolerant to treatment with anti-TNF-alpha agents.","primaryOutcome":{"measure":"Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Response at Week 16","timeFrame":"Week 16","effectByArm":[{"arm":"Placebo","deltaMin":24.1,"sd":null},{"arm":"Sirukumab 50 mg","deltaMin":40.1,"sd":null},{"arm":"Sirukumab 100 mg","deltaMin":45.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.001"},{"comp":"OG000 vs OG002","p":"< 0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":12},"locations":{"siteCount":201,"countries":["United States","Argentina","Australia","Austria","Belgium","Canada","Croatia","France","Germany","Japan","Lithuania","Mexico","Netherlands","New Zealand","Poland","Portugal","Puerto Rico","Russia","South Korea","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":["28215362"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":294},"commonTop":["Rheumatoid Arthritis","Injection Site Erythema","Upper Respiratory Tract Infection","Nasopharyngitis","Alanine Aminotransferase Increased"]}}